当前位置：
X-MOL 学术
›
J. Gynecol. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Primary platinum resistance and its prognostic impact in patients with recurrent ovarian cancer: an analysis of three prospective trials from the NOGGO study group.
Journal of Gynecologic Oncology ( IF 3.4 ) Pub Date : 2021-4-8 , DOI: 10.3802/jgo.2021.32.e37 Fabian Trillsch 1 , Sven Mahner 1 , Bastian Czogalla 1 , Miriam Rottmann 2 , Radoslav Chekerov 3 , Elena Ioana Braicu 3 , Gülten Oskay-Öczelik 4 , Pauline Wimberger 5 , Rolf Richter 3 , Jalid Sehouli 3
Journal of Gynecologic Oncology ( IF 3.4 ) Pub Date : 2021-4-8 , DOI: 10.3802/jgo.2021.32.e37 Fabian Trillsch 1 , Sven Mahner 1 , Bastian Czogalla 1 , Miriam Rottmann 2 , Radoslav Chekerov 3 , Elena Ioana Braicu 3 , Gülten Oskay-Öczelik 4 , Pauline Wimberger 5 , Rolf Richter 3 , Jalid Sehouli 3
Affiliation
Patients with platinum-resistant ovarian cancer (PROC) have a high need for reliable prognostic markers. Since significance of primary platinum resistance (PPR) versus secondary platinum resistance (SPR) was identified for patients receiving anti-angiogenic therapy, it has not been confirmed for chemotherapy only.
中文翻译：
原发性铂耐药及其对复发性卵巢癌患者的预后影响：对来自 NOGGO 研究组的三项前瞻性试验的分析。
铂耐药性卵巢癌 (PROC) 患者非常需要可靠的预后标志物。由于在接受抗血管生成治疗的患者中确定了原发性铂类耐药 (PPR) 与继发性铂类耐药 (SPR) 的显着性，因此尚未证实仅用于化疗。
更新日期：2021-04-11
中文翻译：
原发性铂耐药及其对复发性卵巢癌患者的预后影响：对来自 NOGGO 研究组的三项前瞻性试验的分析。
铂耐药性卵巢癌 (PROC) 患者非常需要可靠的预后标志物。由于在接受抗血管生成治疗的患者中确定了原发性铂类耐药 (PPR) 与继发性铂类耐药 (SPR) 的显着性，因此尚未证实仅用于化疗。
京公网安备 11010802027423号